Medullary Thyroid CarcinomaNCT07713901
Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
An observational study of Medullary Thyroid Carcinoma, run by Novo Nordisk A/S at 1 site in United States.
Trial summary
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Medullary Thyroid Carcinoma
- What is being tested?
- No treatment given
- How many people
- 93,600,000 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Dec 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of adults aged 18 years and older in the United States who are receiving routine treatment for type 2 diabetes or weight management and are identified utilizing real-world data (RWD).
Who may be able to join
- 18 years or older during the year of index (date of qualifying medication)
- In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1
- ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)
- No evidence of cohort qualifying medication during 12-month before the index date
- Reside in the US, including the District of Columbia (DC) during the study period
- No missing values for year of birth
Who cannot join
- Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.
- Conditions
- Medullary Thyroid Carcinoma
- Being tested
- No treatment given
- Medical subject headings
- Carcinoma, Medullary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No treatment givenOther
No treatment given
| Study group | Role | What they receive |
|---|---|---|
| Long-acting GLP-1 RA Exposed Cohort | Participants will be eligible for inclusion in this cohort if they have at least one dispensed prescription for a LA GLP-1 RA therapy during the study patient selection period. Receives: Other: No treatment given | |
| T2D Active Comparator 1 Cohort | Participants will be included in this cohort if they fill at least one dispensed prescription for SGLT2 or DPP-4 inhibitors during the study patient selection period with no evidence of SGLT2 or DPP-4 inhibitors and without LA GLP-1 RA use during the prior 12-month lookback period. Receives: Other: No treatment given | |
| T2D Active Comparator 2 Cohort | Participants will be included in this cohort if they fill at least one dispensed prescription for any antidiabetic medications (including SGLT2 or DPP-4 inhibitors), other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period. Receives: Other: No treatment given | |
| Overweight/Obesity Active Comparator Cohort | Participants will be included in this cohort if they fill at least one dispensed prescription for anti-obesity medications, other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period. Receives: Other: No treatment given |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to first occurence of Medullary Thyroid Carcinoma (MTC)
Measured in number of days.
Measured: From day 1 up to 15 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2026
- Study start31 Dec 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medullary Thyroid CarcinomaStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 93,600,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07713901
- Sponsor's protocol ID
- NN2211-8841
- Other IDs
- U1111-1341-5652
- Status last verified
- Aug 2026
- First submitted
- 15 Jul 2026
- Last updated
- 4 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
- ClinicalTrials.gov ID
- NCT07713901
- Acronym / sponsor ID
- NN2211-8841
- Conditions
- Medullary Thyroid Carcinoma
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 93,600,000 participants (estimated)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 31 Dec 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 20 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Long-acting GLP-1 RA Exposed Cohort | – | Other: No treatment givenParticipants will be eligible for inclusion in this cohort if they have at least one dispensed prescription for a LA GLP-1 RA therapy during the study patient selection period. |
| T2D Active Comparator 1 Cohort | – | Other: No treatment givenParticipants will be included in this cohort if they fill at least one dispensed prescription for SGLT2 or DPP-4 inhibitors during the study patient selection period with no evidence of SGLT2 or DPP-4 inhibitors and without LA GLP-1 RA use during the prior 12-month lookback period. |
| T2D Active Comparator 2 Cohort | – | Other: No treatment givenParticipants will be included in this cohort if they fill at least one dispensed prescription for any antidiabetic medications (including SGLT2 or DPP-4 inhibitors), other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period. |
| Overweight/Obesity Active Comparator Cohort | – | Other: No treatment givenParticipants will be included in this cohort if they fill at least one dispensed prescription for anti-obesity medications, other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of adults aged 18 years and older in the United States who are receiving routine treatment for type 2 diabetes or weight management and are identified utilizing real-world data (RWD).
Key inclusion criteria (6 listed)
- 18 years or older during the year of index (date of qualifying medication)
- In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1
- ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)
- No evidence of cohort qualifying medication during 12-month before the index date
- Reside in the US, including the District of Columbia (DC) during the study period
Key exclusion criteria (1 listed)
- Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No treatment givenNo treatment given | Other | Long-acting GLP-1 RA Exposed Cohort, Overweight/Obesity Active Comparator Cohort, T2D Active Comparator 1 Cohort, T2D Active Comparator 2 Cohort |
Primary outcome
Time to first occurence of Medullary Thyroid Carcinoma (MTC)
Time frame: From day 1 up to 15 years
Measured in number of days.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Medullary Thyroid Carcinoma
RecruitingPhase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Active, not recruitingObservational study
Natural History Study of Children and Adults With Medullary Thyroid Cancer
Medullary Thyroid Cancer
Not yet recruitingPhase 1
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Renal Cell Carcinoma
Active, not recruitingPhase 1
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Anal Carcinoma, Bladder Carcinoma
Active, not recruitingPhase 4
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Medullary Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Clinical Transparency (dept. 2834) study director
Novo Nordisk A/S
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Medullary Thyroid Carcinoma, run by Novo Nordisk A/S at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to first occurence of Medullary Thyroid Carcinoma (MTC) (time frame: From day 1 up to 15 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.